News

 

At AseBio, we follow the latest news in the biotechnology sector and pass the highlights on to you. You can use the search engine to find news articles we’ve written, contributed by our members or from other stakeholders in the sector. And they are also organised into categories to help you find the topics you’re interested in easily.

Search engine
foto oryzon 2
ORYZON presents iadademstat ALICE 30-month data at EHA-2021, confirming positive and robust efficacy in combination with azacitidine in AML
Healthcare
Robust signals of clinical efficacy, with ORR of 83%, of which 67% are CR/CRi and five…
genesis biomed
Algorithms and Image Biomarkers. Radiomics as another piece of precision oncology
Personalized medicine
Radiomics is revolutionising medical image interpretation
lim global
LIM Global, Digital transformation and rebranding by eMascaró
The objectives were clear: communicate the brand's values, encourage customer attraction, entice…
owl
OWL Metabolomics and Sagimet Biosciences closed an agreement to use OWL´s services in Sagimet´s Phase 2b FASCINATE-2 Clinical Trial
Healthcare
In a recent Phase 2a trial, TVB-2640 improved serum biomarkers of liver injury in patients with…
Ysios Capital anuncia la salida a bolsa en el NASDAQ de su compañía participada CVRx, Inc.
Ysios Capital closes its third fund at €216 million ($260 million)
Ysios BioFund 3 (YBF 3) is the firm’s largest fund to date. To invest in up to 15 companies in…
foto noticia asabys
Asabys Partners certifies with Bureau Veritas its Social Responsibility Management System aligned with the Sustainable Development Goals (SDGs) from United Nations
Financing
Asabys, who has been in business for almost 3 years, has considered sustainability as a fundamental…
oryzon
ORYZON to present new clinical data and corporate updates at international conferences in May and June
Healthcare
The conferences are: BioEquity Europe Digital, Foro Medcap BME 2021, Oxford Global’s Online Drug…
edificio oryzon
ORYZON reports results and corporate update for quarter ended March 31, 2021
Healthcare
La compañía invierte 3,6 M€ en I+D sin impactos significativos derivados de la pandemia covid-19
3P Facilities
3P Biopharmaceuticals and Buzzard Pharmaceuticals start a collaboration to develop a new treatment to combat solid tumours
Healthcare · Innovative drugs · Advanced therapies · BioSpain
3P Biopharmaceuticals and Buzzard Pharmaceuticals have entered into a partnership agreement…